Introduction
Cyclooxygenase-2 (COX-2) is an inducible enzyme that converts arachidonic acid to prostaglandins, which play a role in cell proliferation and are potent mediators of inflammation (1) . Furthermore, COX-2 has been postulated to influence carcinogenesis by inhibiting apoptosis (2) , inducing angiogenesis (3) and by chronic activation of immune responses (4) . Several studies have shown increased expression of COX-2 in various cancers (5) (6) (7) . Increased COX-2 expression has also been observed in prostate tumours (8, 9) , although it has been suggested that the over-expression is confined to proliferative inflammatory atrophy (10) , a precursor of prostate cancer.
Even though a number of single-nucleotide polymorphisms (SNPs) have been reported in COX-2, only a few SNPs have been identified in the coding regions, suggesting evolutionary selection in favour of maintaining the enzyme's role in body homeostasis (11) . Genetic associations between allelic variations in the COX-2 non-coding, promoter and 3# untranslated region and risk of developing different forms of cancer have been demonstrated (12, 13) . Moreover, progressively more associations between COX-2 SNPs and risk of developing prostate cancer have been reported. Panguluri et al. (14) described an increased risk of prostate cancer in African American men and variants in the COX-2 promoter that alter putatively functional transcription factor-binding sites. They additionally identified a COX-2 promoter haplotype that conferred increased risk of prostate cancer in African American and Nigerian men (14) . Subsequent studies described a decreased risk of developing prostate cancer in Swedish men with the intronic COX-2 polymorphisms rs20432 (þ3100T.G) and rs689470 (þ8365G.A) (15) and North American Caucasian men with rs2745557 (þ202G.A) and rs2206593 (þ6994C.T) (16). Cheng et al. (16) additionally reported a higher risk of prostate cancer in African American men with the AA genotype of the COX-2 þ8365G.A polymorphism, but no association in Caucasian men. More recent findings from a large case-control study in North American non-Hispanic Caucasian men did not support associations between five SNPs and prostate cancer risk (17) , which included SNPs where associations had been described in other investigations (15, 16) .
In the present study, our aim was to examine the role of COX-2 polymorphisms and the risk of developing prostate cancer in a casecontrol study of South African Coloured men (Coloured refers to a unique South African population group of mixed racial origin). We describe a genetic association between promoter SNPs and a haplotype that confer increased prostate cancer risk. Our findings are to a degree similar to a previously described association between COX-2 promoter polymorphisms and haplotype identified in African American and Nigerian men.
Materials and methods

Study population
Unrelated male subjects from the South African Coloured ethnic group (18) were enrolled in the case-control study to determine genetic risk factors for prostate cancer that was conducted between the years 2004 to 2007. The study population comprising 151 cases [mean (range) age: 69 (47-88) years] with histologically confirmed prostate cancer were all from the Western Cape Province of South Africa and had undergone radical prostatectomy, transurethral resection of the prostate or prostatic biopsy at the Department of Urology, Tygerberg Hospital (Cape Town, South Africa). Controls were selected among subjects admitted to the same hospital during the same period and comprised of 134 individuals that were matched for ethnicity and age [mean (range) age: 65 (52-91) years] and were from the same geographical region. The selection criteria of age-, ethnic-, geographical-and institutional-matching increase the likelihood that the controls were representative of the source population of cases.
Blood samples were collected from each subject. Clinical characteristics including prostate-specific antigen, Gleason grade, tumour node metastasis stage, age at diagnosis and family history were obtained from medical records. All controls had prostate-specific antigen levels 2.5 ng/ml and a normal digital rectal examination. All subjects were informed and gave written consent to participate in the study and allow their biological samples to be genetically analyzed, according to the Helsinki declaration. The study was approved by the Stellenbosch University, Faculty of Health Sciences, Committee for Human Research.
SNP genotyping
Genomic DNA was extracted from whole blood using a QIAamp DNA Kit (Qiagen, GmbH, Hilden, Germany). We used ABI 3100 Mutiplex SNaPshot TM Primer extension analysis (Applied Biosystems, Foster City) to screen SNPs in an 1156 bp region in the COX-2 promoter that starts 125 bp upstream of the transcription start site. The outer primer set for amplification of the 1156 bp fragment were COX-2prmF 5#-CTCACATGCTCCTCCCTGAG-3# and COX2prmR 5#-CTCCTCTCCCCTTAAAAAAATTGCG-3#. Our aim was to replicate the study by Panguluri et al. (14) and therefore we selected the SNPs rs3918304 (À1285A.G), rs20415 (À1265G.A), rs20417 (À899G.C) and rs5270 (À297C.G). The respective primers for the primer extension analysis were À1285 F 5#-CCATCTAATTAATTCCTCATCCAACT-3#, À1265 R 5#-GGCTTATTGGGGCTAATTTT-3# (reverse extension direction in this study), À899 F 5#-TTAGGACCAGTATTATGAGGAGAATTTACCTTTCCC-3# and À297 F 5#-CAGCTTCCTGGGTTTCCGATTTTCTCATTT-3#. Initially, we determined the allele frequency for each SNP in a panel of 50 control subjects.
Abbreviations: C/EBP, CCAAT/enhancer-binding protein; CI, confidence interval; COX-2, cyclooxygenase-2; OR, odds ratio; SNP, single-nucleotide polymorphism.
Among our controls, SNP rs20417 was monomorphic and it was subsequently removed from further genotype analysis.
To determine whether population stratification might be a confounding factor leading to spurious associations (19) , genotype analysis was performed in a group of 65 cases and 65 controls for 24 independent polymorphic SNPs that were not in linkage disequilibrium with COX-2.
Statistical analyses
Genotype and allele frequencies were calculated for each SNP. Each polymorphism was tested in the controls to confirm that they were in HardyWeinberg equilibrium and linkage disequilibrium between polymorphisms was assessed. For each SNP, logistic regression was used to estimate prostate cancer-genotype odds ratios (ORs), 95% confidence intervals (CIs) and corresponding P-values adjusted for age. Logistic regression was combined with an expectation maximization algorithm to infer haplotype frequencies and assess the association between prostate cancer and specific haplotypes. Haplotype analysis inferred a probability distribution of possible haplotypes for each individual. From these, we estimated haplotype frequencies for the group (pooled), as well as separate case and control frequencies. Prostate cancer ORs (and 95% CIs) for specific haplotypes compared with the reference (highest frequency) haplotype were estimated (20) . P-values for prostate cancerhaplotype association were also determined. The OR and P-values are all based on a single model, so that they are all adjusted for each other. Analyses were done in R, a language and environment for statistical computing, freely available from http://www.R-project.org. The R packages genetics, LDheatmap and haplo.stats were used.
Results
All three SNPs were in Hardy-Weinberg equilibrium among the controls (P . 0.05). A significant association with prostate cancer was observed for the À1285 AG/GG (OR 5 3.53; CI 5 2.14-5.90; P , 0.0001) and À1265 CT/TT genotype (OR 5 3.01; CI 5 1.82-5.02; P , 0.0001) after adjusting for age (Table I ). The À297 CG genotype showed an increased risk of prostate cancer (OR 5 2.56; CI 5 0.98-7.58), although this result was not significant after adjustment for age (P 5 0.0673) ( Table I) . No À297 GG genotype was observed in any of the subjects screened in the present study (Table I) . As expected, there was highly significant linkage disequilibrium between the SNP pair À1285/À1265 (Figure 1) .
Our study panel is considered to be a present-day homogeneous population (21), despite historically having received genetic contributions from different ancestral populations (18) . We genotyped a subgroup of 65 cases and 65 controls for a panel of 24 unlinked SNPs in an attempt to address the issue of possible population stratification as a confounding factor leading to spurious associations. To test for stratification across the 24 loci, we calculated the sum of the 24 allelic association v 2 statistics (22), which gave a total of 54.0 at 24 degrees of freedom (P 5 0.0004), indicating that significant stratification exists between the cases and controls included in our study. The median v 2 value for comparison of allele frequencies between cases and controls, among the 24 SNPs, was 1.39 (P 5 0.3557), resulting in an inflation factor of k 5 1.39/0.4549 5 3.06 (23) . All our results remained significant when we inflated our P-values by multiplying them with the inflation factor (data not shown). Additionally, the P-values we obtained for our significant results were much smaller than any of those found for our unlinked independent panel of 24 SNPs, further indication that our results are probably true.
Three haplotypes of À1285A.G, 1265C.T and À297C.G had inferred frequencies of !5% in the study groups (Table II) . Five haplotypes with individual frequencies ,5% in the study groups were grouped together for the analysis (Table II) . The global P-value for the fit of the logistic regression model of prostate cancer case-control status was highly significant (P , 0.0001). Haplotype GTC, compared with the haplotype ACC, was associated with prostate cancer in South African Coloured men (OR 5 3.54; CI 5 2.12-5.92) ( Table II) . Highly significant (P , 0.0001 after inflating) differences in haplotype frequencies between cases and controls were found for both haplotypes ACC (52% in cases and 73% in controls) and GTC (31% in cases and 16% in controls) (Table II) . 
Discussion
The present study identified two SNPs and a haplotype in the COX-2 promoter that are associated with prostate cancer risk in South African Coloured men. A previous study reported an increased association between prostate cancer and having the À1265 A-allele and À899 C-allele and an inverse association with the À297 G-allele (14) . In our study, we found that the À1265 T-allele increased the risk of prostate cancer, which confirms the association described by Panguluri et al. (14) . However, our study differs marginally because the À899G.C SNP was excluded from this investigation, an increased risk of prostate cancer was identified with the À1285 G-allele and no statistically significant association was observed with the À297 G-allele. Our study demonstrated that the GTC haplotype increases the risk of developing prostate cancer by 3.54-fold in South African Coloured men compared with the ACC haplotype. We also noted that the ACC haplotype occurred with a significantly higher frequency in the controls than in the cases. This finding could possibly suggest that this haplotype could be protective against developing prostate cancer in South African Coloured men. The promoter region upstream of the COX-2 transcriptional start site contains multiple putative transcription factor-binding sites (1, 24) . Several studies have described an elevated COX-2 expression in prostate tumours (8, 9, 25, 26) , although one study suggested that increased COX-2 levels may suppress tumour development (27) . In the present study, two promoter variants were shown to be associated with prostate cancer. The À1285A.G variant does not alter a promoter transcriptional factor site, whereas the À1265 A-allele putatively eliminates a CCAAT/enhancer-binding protein (C/EBP) a site and creates a Pit-1a-and Hb-binding site (14) . Increased levels of C/EBPa have been shown to down-regulate COX-2 expression in mouse skin carcinoma cells (28) , whereas another study demonstrated that up-regulation of COX-2 is associated with decreased levels of C/EBPa in rat hepatocytes (29) . The third polymorphism analyzed in this study (À297C.G) has been shown to create a C/EBP delta (d)-and a ribosomal DNA-binding site (14) . Interestingly, increased COX-2 expression in mouse skin carcinogenesis has been correlated with decreased levels of C/EBPa and concomitant increased C/EBPd expression (28) . At present, it is not yet known whether the elimination of a C/EBPa site and creation of a C/EBPd site may independently or synergistically alter the expression of COX-2.
Numerous investigations have shown that sub-Saharan, West and Central African and African American populations are related genetically (30, 31) , and suggestions have been made that common susceptibility alleles are probably to be present across different African populations (32) . Increased genetic risk between COX-2 variants and prostate cancer has been shown in African American (14, 16) and Nigerian men (14) ; concomitantly, these studies reported reduced risk between COX-2 variants and prostate cancer in Caucasian men. High incidence rates of prostate cancer have been detected in South African Coloured men (33), a unique ethnic group descendant predominantly of Khoi and San (African) inhabitants, with genetic contributions from European settlers (predominantly Dutch, German and French) and Asian (Indonesian and Madagascan) migrants who inhabited the Western Cape Province of South Africa in the late 1600s (18) . Taken together, the genetic association described in this Southern African population in conjunction with findings in other populations of African descent (14,16) might suggest a common causal variant for prostate cancer in COX-2 or a variant in a nearby gene.
Our study has a number of weaknesses and strengths. The sample size was relatively small, although it was sufficient to detect small to moderate associations. Our control group was closely matched to the cases by age, ethnicity, geography and medical institution to reduce the likelihood of spurious association due to population stratification. When we tested a panel of cases and controls for 24 independent SNPs, we observed significant stratification between the groups. However, even after genomic control inflation of our P-values, the results remained highly significant. The genetic association was detected in a male population of mixed African, European and Asian descent and it should be researched in other South African ethnic groups (Black African and Caucasian). A limitation of the study is that the SNPs that were selected only provide a limited coverage of COX-2. Further investigations should be undertaken on additional COX-2 SNPs, on variants in genes flanking COX-2 and in other genes in the inflammatory pathway.
In conclusion, we have detected a significant genetic association between variants in COX-2 and prostate cancer risk in South African men. These findings provide supporting evidence to the link between inflammation and prostate cancer. Genotype analyses of additional gene variants are warranted and the influence of the COX-2 promoter variants on gene expression requires investigation. Haplotypes with joint/pooled frequencies ,5% were grouped together. No P-value is given for prostate cancer-rare haplotype association, because it is not a single haplotype.
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